Year1
- 1：
- 4
- 1：
- 5
- 2：
- 6
|Approved the generic version of Gleevec, which is expected to be launched in the United States on October 1st next year
Recently, the United States approved the generic version of Gleevec (Gleevec) from an Indian company, imaginate mesylate. Tinib and is expected to be launched in the United States on January 1 next year. The approved dosage form is tablet, with specifications including and. Because the company is the first company to submit an application for this generic drug, the company will receive a one-month market exclusivity period in accordance with the U.S. Anti-Virus Act.
Gleevec was approved by the United States for the treatment of chronic myelogenous leukemia in 2006. Gleevec is the best-selling product of Novartis, with annual global sales reaching US$100 million, and sales in the US market of US$100 million, accounting for 30% of the entire US oncology drug market. Currently, Gleevec costs about $10,000 per month in the United States, with one pill taken daily.
The approval was unexpected by the company. Last year, Novartis and the company reached a consensus on the patent dispute over Gleevec, and the company agreed to delay the launch of the generic product for a month. This month brought Novartis nearly $100 million in revenue.
The launch of the company's Gleevec generic drug will have little impact on Novartis, because the global sales of Novartis's other drug for chronic myelogenous leukemia (nilotinib) have reached 100 million U.S. dollars. , sales in the US market have exceeded 100 million US dollars. It has a significant effect on patients with chronic myelogenous leukemia (CML) who are resistant or intolerant to Gleevec (Imatinib).
An analyst from .com said the company's conservative sales of Gleevec's generic drug during the one-month exclusivity period ranged from 100 million to 300 million U.S. dollars.
Reno will read the news with you: As the first molecularly targeted anti-tumor drug to be launched, Gleevec must be familiar to everyone. The advent of Gleevec opened a new era for targeted molecular therapy of tumors. So far, global pharmaceutical companies are developing more than three types of molecular-targeted anti-tumor drugs. The advent of Gleevec has also accelerated the approval of multiple enzyme-targeted anti-tumor drugs in the United States. It can be said that Gleevec has won many honors while saving the lives of a large number of patients. For example, Gleevec has been named one of the world's top ten scientific breakthroughs of the year by Science magazine, and its main researchers have won the European Invention of the Year Award and the B Clinical Medical Research Award.
Gleevec has been imported into China. The imported dosage forms include tablets (specifications: and ) and capsules (specifications: ). The retail price of Gleevec in China is 3 yuan/box (*tablets). In addition, three domestic companies, Jiangsu Hansoh, Chia Tai Tianqing and CSPC Ouyi Pharmaceutical, have obtained production approval documents for preparations related to this product approved by my country.
| Approval of the first drug for lysosomal acid lipase deficiency
Recently, the company’s drug for lysosomal acid lipase deficiency was approved. It was the first drug approved for treatment. This month, the European Union approved the drug for the treatment of patients of all ages.
Renault accompanies you to read the news: It is a rare disease, a chronic progressive metabolic disease mainly caused by gene mutations. This gene mutation will lead to a significant reduction in the activity of lysosomal acid lipase in various tissues and organs of the body. This results in the chronic accumulation of cholesterol esters and triglycerides in the liver, blood vessel walls, and other tissues. The main clinical manifestations include hepatosplenomegaly, fibrosis, cirrhosis and liver failure. Infants, children, and adults with this disease eventually die from multiple tissue and organ damage.
| Scientists invent the world's first transparent ibuprofen patch
Ibuprofen cream is a very effective painkiller. Recently, researchers from the University of British R and the company developed the world's first transparent ibuprofen patch. The transparent polymer base film uses the adhesive technology of Company B to increase the drug loading capacity by 3. The drug effect is currently the most transdermal. - times the amount of patch or gel. At the same time, the analgesic effect of ibuprofen can be sustained for hours. In addition, the transparent poly film does not stain clothes and is not easy to fall off, so it is very suitable for wounds that wear close-fitting clothing or are subject to frequent friction. Strictly speaking, this product will be a superior long-acting alternative for patients who are intolerant to oral ibuprofen doses or are potentially at risk for common pain conditions such as chronic back pain, neuralgia, and arthritis.
Reynold will accompany you to read the news: Ibuprofen is a non-steroidal anti-inflammatory drug that has been used clinically for many years. Ibuprofen is widely used in different departments because of its precise anti-inflammatory, antipyretic and analgesic effects, small side effects, and easy absorption after oral administration. It has a very good therapeutic or auxiliary treatment effect on various pediatric diseases. . Ibuprofen, acetaminophen and aspirin are among the three main antipyretics and analgesics, and have become the best-selling over-the-counter drugs in the world. In addition, ibuprofen is the only antipyretic drug for children recommended jointly with the United States.
Clinical trials have confirmed that when the body temperature is higher than 3.℃, the antipyretic effect of ibuprofen is better than that of acetaminophen at the same dose, and the antipyretic time is longer. Compared with aspirin, the analgesic effect of ibuprofen is ~3 times stronger than that of aspirin, and its antipyretic effect is similar to that of aspirin but longer lasting than aspirin. Ibuprofen is suitable for relieving acute attacks or persistent joint swelling and pain symptoms of various chronic arthritis, such as rheumatoid arthritis, osteoarthritis, spondyloarthritis, gouty arthritis, rheumatoid arthritis, etc., and treating non-articular arthritis. It can treat various soft tissue rheumatic pains, acute mild and moderate pain, such as after surgery, trauma, strain, primary dysmenorrhea, toothache and headache, etc. It has antipyretic effect on fever in adults and children.
In 2019, the global market sales of major non-steroidal anti-inflammatory drugs were US$. . According to statistics, a total of 2 dosage forms related to ibuprofen have been approved in my country. Among them, oral preparations are mainly used, and the dosage forms covered include tablets, capsules, granules, etc. See table for details.
WhatsApp
